Trospium chloride controlled release

Drug Profile

Trospium chloride controlled release

Alternative Names: Regurin XL; Sanctura XR; Trospium chloride extended release

Latest Information Update: 23 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indevus Pharmaceuticals
  • Developer Endo Pharmaceuticals Solutions
  • Class Antispasmodics; Benzhydryl compounds; Benzilates; Esters; Nortropanes; Small molecules; Spiro compounds
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Overactive bladder

Most Recent Events

  • 12 Oct 2012 First generic equivalent approved in USA for Overactive bladder
  • 26 Sep 2009 Quintiles Transnational and Allergan agree to co-promote Extended-release trospium chloride in the USA for Overactive bladder
  • 07 Sep 2009 Launched for Overactive bladder in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top